High-tech Pharmaceutical Substances Manufacture: Control Points

Yu.N. Karpova, External PhD Student, Moscow Technological University, Moscow, Russia, yulia_karpova@inbox.ru

Dr. E.G. Khomutova, Professor, Moscow Technological University, Moscow, Russia, khomutova@mail.ru

key words

critical control point, control point, pharmaceutical substance, typed manufacturing process


We have analyzed the domestic and international regulation, documents and proposed a methodology for determining critical control points in the production of high-tech synthetic pharmaceutical substances.

We presented the results of the analysis of regulatory documents to justify the introduction of the new term checkpoint, formulated the definition. For unification, we proposed to use the term control points, which combine the terms control point and critical control point. A selection of control points for a typed production scheme for a pharmaceutical substance of a synthetic nature is described.

To produce a high-tech substance of a synthetic nature, it is recommended to apply the principle of typification in describing the process and its subsequent analysis in order to improve production. Management of the production process is carried out at critical control points, for the identification of which it is necessary to propose an algorithm based on risk assessment. Evaluation should be based on the influence of the process parameter on the quality score.

1. RF Ministry of Industry and Trade order on 23.10.2009 N 956 Strategy for the development of the pharmaceutical industry for the period up to 2020.
2. VP-P8-2322. Comprehensive program for the development of biotechnologies in the Russian Federation for the period up to 2020.
3. Smirnov Yu.G., Shpak O.V., Semenov V.I., Mokeeva V.N., Levagina I.N. Analiz okhranyaemykh rezul’tatov intellektual’noy deyatel’nosti
v farmatsevticheskoy otrasli [Analysis of the protected results of intellectual activity in the pharmaceutical industry], Moscow, INIC Patent,
4. Polonskaya I.V., Serova M.A., Fetina V.N., Kabalkina B.M. Patentnaya ekspertiza za rubezhom [Patent examination abroad], Moscow,

INIC Patent, 2012.

5. RF Ministry of Industry and Trade order on 14.06.2013 N 916 On the approval of the rules of good clinical practice, Konsul’tantPlyus.
6. GOST R 52249–2009 Rules for the production and control of medicinal products, Konsul’tantPlyus.
7. GOST R 52537–2006 Manufacture of medicines. Quality assurance system. General requirements of means, Konsul’tantPlyus.
8. RF Federal Law on 12.04.2010 N 61 On the circulation of medicinal products, Konsul’tantPlyus.
9. EMA/CHMP/ICH/167068/2004 — ICH guideline Q8 (R2) on pharmaceutical development, 2006;
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_ 000789.jsp&mid=WC0b01ac0580028eb2.
10. CPMP/ICH/4106/00 — ICH Topic Q 7 Good Manufacturing Practice for Active Pharmaceutical Ingredients, 2000;
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_ content_ 001323.jsp&mid=WC0b01ac0580029593.
11. Application of Hazard Analysis and Critical Control Point (HACCP) methodology to pharmaceuticals. WHO Technical Report Series.
2003; 908 (Annex 7): 99–112.